ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Childhood immunization barriers and interventions in low- and middle-income countries: A scoping review of access, delivery systems, and health literacy.Human vaccines & immunotherapeutics · 2026Article
- Livestock immunomodulators as alternatives to antimicrobials - a roadmap for the fight against drug resistance.BMC veterinary research · 2026Review
- Exploring the global, regional, and Chinese disease burden of acute glomerulonephritis from 1990 to 2021 and future trends up to 2039 based on the 2021 Global Burden of Disease Database.International urology and nephrology · 2026Article
- Global vaccine development.Nature medicine · 2026Review
- Prevention as a Pillar of Communicable Disease Control: Strategies for Equity, Surveillance, and One Health Integration.Epidemiologia (Basel, Switzerland) · 2026Article
- Measuring vaccine effects on antibiotic use and antimicrobial resistance in low and middle-income countries: A scoping review of methodological approaches, data sources, metrics, and limitations.PLOS global public health · 2026Article
- Strategies and challenges in containing antimicrobial resistance in East Africa: a focus on laboratory-based surveillance.Antimicrobial resistance and infection control · 2025Article
- Mapping the role of vaccines in combating AMR in the WHO African region: a scoping review and implications for research and policy.BMC infectious diseases · 2025Article
- Serotypes distribution and antibiotic susceptibility of Streptococcus pneumoniae strains: five-year surveillance results of post-PCV-13.BMC pediatrics · 2025Article
- Observational study of antibiotic prescribing patterns by age and sex in primary care in England: why we need to take this variation into account to evaluate antibiotic stewardship and predict AMR variation.JAC-antimicrobial resistance · 2025Article
- Global, regional, and national burden of acute glomerulonephritis from 1990 to 2021 and future trend predictions until 2036: a systematic analysis using the Global Burden of Disease Study 2021.Frontiers in public health · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses an immediate danger to global health. If unaddressed, the current upsurge in AMR threatens to reverse the achievements in reducing the infectious disease-associated mortality and morbidity associated with antimicrobial treatment. Consequently, there is an urgent need for strategies to prevent or slow the progress of AMR. Vaccines potentially contribute both directly and indirectly to combating AMR. Modeling studies have indicated significant gains from vaccination in reducing AMR burdens for specific pathogens, reducing mortality/morbidity, and economic loss. However, quantifying the real impact of vaccines in these reductions is challenging because many of the study designs used to evaluate the contribution of vaccination programs are affected by significant background confounding, and potential selection and information bias. Here, we discuss challenges in assessing vaccine impact to reduce AMR burdens and suggest potential approaches for vaccine impact evaluation nested in vaccine trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.